drugset / Trial / NCT02617134
CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor
Phase 1/2
Unknown
20 enrolled
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Hefei Binhu Hospital · collabThe First People's Hospital of Hefei · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in patients with MUC1 positive relapsed or refractory solid tumor.
Timeline
- Start
- 2015-11
- Primary completion
- 2017-11
- Completion
- 2018-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anti-MUC1 CAR-T cells | Cell therapy | — | Other |